Revista de Revistas.

Farmacoterapia en el paciente suicida. Pharmacotherapy of the suicidal patient P Kragh-Sorensen Acta Psychiatr Scand 1993: Suppl 371. M. A. Casado Fumar cigarrillos: sus implicaciones en trastornos psiquiátricos. Cigarrette smoking: Implications for psychiatric illness A.H. Glassman Am. J. Psychiatry 1993; 150: 546·553. J. Jáuregui Isasmendi Síndrome de Gilles de la Tourette: un trastorno neuropsiquiátrico. Gilles de la Tourette Syndrome: a neuropsychiatric disorder P Sandor Journal of Psychomatic Research 1993; 37 (3): 211-226. M.T. de Lucas Taracena Curso Clínico de 636 pacientes alcohólicos hospitalizados. M.A. Schuckit, T.L. Smith, R. Anthenelli, M. Irwin American Journal of Psych. May 1993; 150, 5: 786-791. M.1. de la Hera Cabero Pérdida de los efectos del tto. tras terapia continuada. FM. Quitkin, J.W Stewart, PJ. McGrath, E. Nunes, K. Ocepek-Welikson, E. Tricamo, J.G. Rabkin, o. Ross, o.F Klein American Journ. of Psych. April 1993; 150, 4: 562-565. M.I. de la Hera Cabero "Acting out" y temas de transferencia inducidos por sucesivos embarazos de la analista. Acting out and transference themes induced by succesive pregnancies of the analyst M. Deben-Mager. El embarazo de la analista y sus consecuencias sobre su trabajo. The analyst's preganacy and its consequences on her work. A. Etchegoyen. El embarazo de la analista: el paciente, la analista y el espacio de lo desconocido. The analyst's pregnancy: the patient, the analyst and the space of the unknown P Mariotti En The International Journal of Psycho-Analysis. febrero 1993; vol 74, parto 1: pags 129-139, 141-149, 151-164 respectivamente. Escudero Nafs,

Revista de Revistas.

Farmacoterapia en el paciente suicida. Pharmacotherapy of the suicidal patient P Kragh-Sorensen Acta Psychiatr Scand 1993: Suppl 371. M. A. Casado Fumar cigarrillos: sus implicaciones en trastornos psiquiátricos. Cigarrette smoking: Implications for psychiatric illness A.H. Glassman Am. J. Psychiatry 1993; 150: 546·553. J. Jáuregui Isasmendi Síndrome de Gilles de la Tourette: un trastorno neuropsiquiátrico. Gilles de la Tourette Syndrome: a neuropsychiatric disorder P Sandor Journal of Psychomatic Research 1993; 37 (3): 211-226. M.T. de Lucas Taracena Curso Clínico de 636 pacientes alcohólicos hospitalizados. M.A. Schuckit, T.L. Smith, R. Anthenelli, M. Irwin American Journal of Psych. May 1993; 150, 5: 786-791. M.1. de la Hera Cabero Pérdida de los efectos del tto. tras terapia continuada. FM. Quitkin, J.W Stewart, PJ. McGrath, E. Nunes, K. Ocepek-Welikson, E. Tricamo, J.G. Rabkin, o. Ross, o.F Klein American Journ. of Psych. April 1993; 150, 4: 562-565. M.I. de la Hera Cabero "Acting out" y temas de transferencia inducidos por sucesivos embarazos de la analista. Acting out and transference themes induced by succesive pregnancies of the analyst M. Deben-Mager. El embarazo de la analista y sus consecuencias sobre su trabajo. The analyst's preganacy and its consequences on her work. A. Etchegoyen. El embarazo de la analista: el paciente, la analista y el espacio de lo desconocido. The analyst's pregnancy: the patient, the analyst and the space of the unknown P Mariotti En The International Journal of Psycho-Analysis. febrero 1993; vol 74, parto 1: pags 129-139, 141-149, 151-164 respectivamente. Escudero Nafs,

Síndrome de Cushing: una causa infrecuente de hiperglucemia.

El síndrome de Cushing ectópico (SCE) se produce como resultado de la producción de la hormona adrenocorticotropa (ACTH) desde neoplasias extrahipofisarias. El SCE es un problema médico poco frecuente y difícil de diagnosticar. Se presenta el caso de un varón de 55 años, fumador activo, sin antecedentes médicos relevantes, que acude al servicio de urgencias por polidipsia y poliuria. Finalmente, tras diversas pruebas complementarias, se establece el juicio clínico de síndrome de Cushing secundario a un carcinoma de célula pequeña

Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study

<p>Abstract</p> <p>Background</p> <p>Little information is available on the effect of allergen-specific immunotherapy on airway responsiveness and markers in exhaled air. The aims of this study were to assess the safety of immunotherapy with purified natural Alt a1 and its effect on airway responsiveness to direct and indirect bronchoconstrictor agents and markers in exhaled air.</p> <p>Methods</p> <p>This was a randomized double-blind trial. Subjects with allergic rhinitis with or without mild/moderate asthma sensitized to <it>A alternata </it>and who also had a positive skin prick test to Alt a1 were randomized to treatment with placebo (n = 18) or purified natural Alt a1 (n = 22) subcutaneously for 12 months. Bronchial responsiveness to adenosine 5'-monophosphate (AMP) and methacholine, exhaled nitric oxide (ENO), exhaled breath condensate (EBC) pH, and serum Alt a1-specific IgG₄antibodies were measured at baseline and after 6 and 12 months of treatment. Local and systemic adverse events were also registered.</p> <p>Results</p> <p>The mean (95% CI) allergen-specific IgG₄value for the active treatment group increased from 0.07 μg/mL (0.03-0.11) at baseline to 1.21 μg/mL (0.69-1.73, P < 0.001) at 6 months and to 1.62 μg/mL (1.02-2.22, P < 0.001) at 12 months of treatment. In the placebo group, IgG₄value increased nonsignificantly from 0.09 μg/mL (0.06-0.12) at baseline to 0.13 μg/mL (0.07-0.18) at 6 months and to 0.11 μg/mL (0.07-0.15) at 12 months of treatment. Changes in the active treatment group were significantly higher than in the placebo group both at 6 months (P < 0.001) and at 12 months of treatment (P < 0.0001). However, changes in AMP and methacholine responsiveness, ENO and EBC pH levels were not significantly different between treatment groups. The overall incidence of adverse events was comparable between the treatment groups.</p> <p>Conclusion</p> <p>Although allergen-specific immunotherapy with purified natural Alt a1 is well tolerated and induces an allergen-specific IgG₄response, treatment is not associated with changes in AMP or methacholine responsiveness or with significant improvements in markers of inflammation in exhaled air. These findings suggest dissociation between the immunotherapy-induced increase in IgG₄levels and its effect on airway responsiveness and inflammation.</p

Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial

BACKGROUND Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress. RESULTS Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group. CONCLUSIONS The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI

Are people following hip and knee arthroplasty at greater risk of experiencing a fall and fracture? Data from the Osteoarthritis Initiative

Introduction: Falls are a major challenge for older people and are a significant source of mortality and morbidity. There has been uncertainty as to whether people with total hip (THA) or knee (TKA) arthroplasty have a greater risk of falls and associated fractures. This analysis was to explore this question with a large community dataset. Materials and Methods: Data from all people enrolled onto the US Osteoarthritis Initiative programme who had undergone a THA (n=104) or TKA (n=165), within a 12 month period, were compared to those who had not undergone an arthroplasty (n=4631). Data was collected on: the number of participants who reported a fall within a 12 month period; the frequency of falls in this period; and whether a fracture was sustained during this period. Odd ratios were calculated for the probability of experiencing a fall or fracture between the groups. Results: There was no statistical difference in falls between people following THA (OR 0.90; 95% CI: 0.58 to 1.41) or TKA (OR: 0.95; 0.67 to 1.35) compared to a non-arthroplasty cohort. Whilst there was no statistical difference in fracture risk between people following TKA compared to non-arthroplasty individuals (OR: 1.25; 95% CI: 0.57 to 2.70), those who underwent THA had a 65% lower chance of experiencing a fracture in the initial 12 post-operative months compared to the non-THA cohort (OR 0.35; 95% CI: 0.19 to 0.65; p<0.01). Conclusions: There appears a lower chance of experiencing a fracture for people following THA compared to those who have not

Eta Carinae and the Luminous Blue Variables

We evaluate the place of Eta Carinae amongst the class of luminous blue variables (LBVs) and show that the LBV phenomenon is not restricted to extremely luminous objects like Eta Car, but extends luminosities as low as log(L/Lsun) = 5.4 - corresponding to initial masses ~25 Msun, and final masses as low as ~10-15 Msun. We present a census of S Doradus variability, and discuss basic LBV properties, their mass-loss behaviour, and whether at maximum light they form pseudo-photospheres. We argue that those objects that exhibit giant Eta Car-type eruptions are most likely related to the more common type of S Doradus variability. Alternative atmospheric models as well as sub-photospheric models for the instability are presented, but the true nature of the LBV phenomenon remains as yet elusive. We end with a discussion on the evolutionary status of LBVs - highlighting recent indications that some LBVs may be in a direct pre-supernova state, in contradiction to the standard paradigm for massive star evolution.Comment: 27 pages, 6 figures, Review Chapter in "Eta Carinae and the supernova imposters" (eds R. Humphreys and K. Davidson) new version submitted to Springe